Alseres Pharmaceuticals Completes Enrollment In First Stage Of The Altropane(R) POET-2 Phase III Program

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), announced that it has completed enrollment in the first stage of the Altropane Parkinson’s or Essential Tremor (POET-2) Phase III clinical program. The objective of the first part of the program was to acquire the set of Altropane images which will be used to train expert readers for the Phase III registration portion of the program.

More: continued here

Filed under: Parkinson's Disease on February 8th, 2009